Guangzhou Innogen climbs on clinical trials approval on obesity drug
22/06/2026 08:36
BUZZ-Guangzhou Innogen climbs on clinical trials approval on obesity drug ** Shares of Guangzhou Innogen Pharmaceutical Group 2591.HK climb 4.4% to HK$7.87, on course for the biggest one-day pct gain since May 19
** Hong Kong-listed pharmaceutical products developer says it has received approval from China's National Medical Products Administration to commence Phase Ib clinical trials for its Efsubaglutide Alfa for the treatment of obesity in adolescents
** Company expects to commence clinical trial in July 2026 and plans to enroll about 36 participants for the clinical trial
** YTD, stock down 74.6%, Hang Seng Biotech Index .HSBIO donw 15.7%
(Reporting by Donny Kwok)
Recent news on Guangzhou Innogen Pharmaceutical
See all newsBrief: Guangzhou Innogen Pharmaceutical Appoints Jin Bai As Vice President
Brief: Guangzhou Innogen Pharmaceutical Says Xu Wenjie Resigns As Executive Director
Brief: Guangzhou Innogen Pharmaceutical Group Co's Founder, Senior Management Undertakes Six-Month Lock-Up
Brief: Guangzhou Innogen Pharmaceutical Announces Intention To Conduct On-Market H Share Repurchase
Brief: GUANGZHOU INNOGEN PHARMACEUTICAL Posts HY LOSS Of RMB115.5 MLN